Players Focus on Developing New Drugs to Capture Greater Share in Ventricular Tachycardia Therapeutics Market

Published Date : May 29, 2017

ALBANY, New York, May 29, 2017: has added a new market study to its repository, titled, “Ventricular Tachycardia - Pipeline Review, H1 2017.” It furnishes thorough details of the therapeutics under development for ventricular tachycardia, which is a very fast heart rhythm – faster than 100 (or 120) beats/min, with 3 or more irregular beats in a row – beginning in the ventricles. Ventricular tachycardia can result in symptoms such as chest pain, dizziness, fainting, fatigue, and shortness of breath. It can be caused by ischemic heart disease, cardiomyopathy, and heart failure. Risk factors include age, medical and family history and treatment includes antiarrhythmic medication. 

The report provides a pipeline guide to ventricular tachycardia which consists of an exhaustive list of therapeutics currently being developed. The report also details the development stage, molecule type, target of the drug, mechanism of action (MoA), and route of administration (RoA).

The report covering the ventricular tachycardia (cardiovascular) pipeline further assesses main players carrying out therapeutic development for ventricular tachycardia. It examines not just ongoing projects but also inactive or discontinued projects. The report casts a proper glance at the different therapeutics being developed by companies, universities, and institutes. It also uncovers that the molecules being developed by companies in preclinical stages, phase II, and phase III are 3, 4, and 1, respectively. 

For Sample Copy, click here:

The report on ventricular tachycardia (cardiovascular) pipeline aids in zeroing in on and tracking upcoming competitors in the market and furnishes information on their portfolios too. It arms players with essential knowledge so as to enable them to take strategic decisions and frame effective roadmaps to stay on top of competition. Some of the key companies that are in the process of coming up with new drugs, profiled in the report are Armetheon Inc., Audentes Therapeutics Inc., HUYA Bioscience International LLC, Gilead Sciences Inc., Ono Pharmaceutical Co Ltd., InCarda Therapeutics Inc., and
Milestone Pharmaceuticals Inc. 

The report on ventricular tachycardia (cardiovascular) pipeline, which is a comprehensive guide is built leveraging data procured from Global Markets Directs proprietary databases, from company and university websites, conferences, clinical trial registries, SEC filings, investor presentations, and press releases on company and university sites and other industry-related third party sources. The study encapsulates only the latest and relevant developments. For example, it talks about Milestone Pharmaceuticals announcing Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia in May 2017 and its presentation of Etripamil Phase 2 Data at the Heart Rhythm Society's 38th Annual Scientific Sessions in April 2017. 

Some such drugs in the pipeline that the report studies are aladorian sodium, budiodarone, etripamil, GS-967, HBI-3000, landiolol, and flecainide acetate. 

To order report Call Toll Free: 866-997-4948 or send an email on